Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Profile Name||KDR R1032Q|
|Gene Variant Detail|
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|KDR R1032Q||colorectal cancer||sensitive||Lenvatinib||Preclinical - Cell culture||Actionable||In a preclinical study, expression of KDR (VEGFR2) R1032Q in a colorectal cancer cell line resulted in increased sensitivity to Lenvima (lenvatinib), leading to increased growth inhibition in culture (PMID: 29588308).||29588308|
|KDR R1032Q||colorectal cancer||sensitive||Cabozantinib||Preclinical - Cell culture||Actionable||In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited reduced ERK phosphorylation and inhibited growth of a colorectal cancer cell line harboring KDR (VEGFR2) R1032Q in culture (PMID: 29588308).||29588308|
|KDR R1032Q||basal cell carcinoma||predicted - sensitive||Pazopanib||Case Reports/Case Series||Actionable||In a clinical case study, Votrient (pazopanib) treatment in a patient with metastatic basal cell carcinoma harboring KDR R1032Q who had progressed on treatment with Erivedge (vismodegib), resulted in a complete response, but treatment was discontinued after 6 months due to toxic effects, and disease relapse followed 3 months later (PMID: 28384659).||28384659|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|